Replicase-based plasmid DNA shows anti-tumor activity

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Rodriguez, B Leticia ^a   Yu, Zhen ^b   Chung, Woon Gye ^a   Weiss, Richard ^c   Cui, Zhengrong ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF SALZBURG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; PLASMID DNA; RNA DIRECTED RNA POLYMERASE; DNA; DNA DIRECTED DNA POLYMERASE; DNA REPLICASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG EFFICACY; FEMALE; GENE DELIVERY SYSTEM; LIPOSOMAL GENE DELIVERY SYSTEM; LUNG CANCER; MELANOMA; MOUSE; NONHUMAN; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; EVALUATION; EXPERIMENTAL MELANOMA; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METHODOLOGY; NEOPLASM; NUDE MOUSE; PATHOLOGY; PLASMID; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DNA; DNA-DIRECTED DNA POLYMERASE; FEMALE; GENE THERAPY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PLASMIDS; TRANSFECTION;

EID: 79953111875     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-110     Document Type: Article

References (45)

1. Absher M, Stinebring WR. Toxic properties of a synthetic double-stranded RNA. Endotoxin-like properties of poly I. poly C, an interferon stimulator. Nature 1969, 223(5207):715-717. 10.1038/223715a0, 5805520.
2. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8(3):237-249. 10.1023/A:1023668705040, 12766484.
3. Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur J Immunol 2006, 36(12):3371-3380. 10.1002/eji.200636053, 17109465.
4. Friedrich I, Shir A, Klein S, Levitzki A. RNA molecules as anti-cancer agents. Semin Cancer Biol 2004, 14(4):223-230. 10.1016/j.semcancer.2004.04.001, 15219615.
5. Cui Z, Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 2006, 55(10):1267-1279. 10.1007/s00262-005-0114-6, 16362407.
6. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413(6857):732-738. 10.1038/35099560, 11607032.
7. Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003, 9(1):33-39. 10.1038/nm813, 1484510, 12496961.
8. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006, 7(2):131-137. 10.1038/ni1303, 16424890.
9. Kumar H, Koyama S, Ishii KJ, Kawai T, Akira S. Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol 2008, 180(2):683-687.
10. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 2006, 80(10):5059-5064. 10.1128/JVI.80.10.5059-5064.2006, 1472073, 16641297.
11. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008, 60(7):805-812. 10.1016/j.addr.2007.11.005, 18262679.
12. Le UM, Yanasarn N, Lohr CV, Fischer KA, Cui Z. Tumor chemo-immunotherapy using gemcitabine and a synthetic dsRNA. Cancer Biol Ther 2008, 7(3):440-447. 10.4161/cbt.7.3.5423, 18094613.
13. Hirabayashi K, Yano J, Inoue T, Yamaguchi T, Tanigawara K, Smyth GE, Ishiyama K, Ohgi T, Kimura K, Irimura T. Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity. Cancer Res 1999, 59(17):4325-4333.
14. Pimm MV, Baldwin RW. Treatment of transplanted rat tumours with double-stranded RNA(BRL 5907). II. Treatment of pleural and peritoneal growths. Br J Cancer 1976, 33(2):166-171. 10.1038/bjc.1976.21, 2024947, 177036.
15. Le UM, Kaurin DG, Sloat BR, Yanasarn N, Cui Z. Localized irradiation of tumors prior to synthetic dsRNA therapy enhanced the resultant anti-tumor activity. Radiother Oncol 2009, 90(2):273-279. 10.1016/j.radonc.2008.10.016, 2741318, 19013656.
16. Sakurai M, Iigo M, Sasaki Y, Nakagawa K, Fujiwara Y, Tamura T, Ohe Y, Bungo M, Saijo N. Lack of correlation between interferon levels induced by polyribonucleotides and their antimetastatic effect. Oncology 1990, 47(3):251-256. 10.1159/000226825, 1692985.
17. Weinstein AJ, Gazdar AF, Sims HL, Levy HB. Lack of correlation between interferon induction and antitumour effect of poly I-poly C. Nat New Biol 1971, 231(19):53-54.
18. Okada C, Akbar SM, Horiike N, Onji M. Early development of primary biliary cirrhosis in female C57BL/6 mice because of poly I:C administration. Liver Int 2005, 25(3):595-603. 10.1111/j.1478-3231.2005.01043.x, 15910497.
19. Shir A, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med 2006, 3(1):e6. 10.1371/journal.pmed.0030006, 1298941, 16318410.
20. Cui Z, Le UM, Qiu F, Shaker DS. Learning from viruses: the necrotic bodies of tumor cells with intracellular synthetic dsRNA induced strong anti-tumor immune responses. Pharm Res 2007, 24(9):1645-1652. 10.1007/s11095-007-9293-5, 17404807.
21. McBride S, Hoebe K, Georgel P, Janssen E. Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J Immunol 2006, 177(9):6122-6128.
22. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljestrom P, Reis e Sousa C. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005, 433(7028):887-892. 10.1038/nature03326, 15711573.
23. Scheiblhofer S, Weiss R, Gabler M, Leitner WW, Thalhamer J. Replicase-based DNA vaccines for allergy treatment. Methods Mol Med 2006, 127:221-235.
24. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 1994, 58(3):491-562. 372977, 7968923.
25. Li ML, Stollar V. Identification of the amino acid sequence in Sindbis virus nsP4 that binds to the promoter for the synthesis of the subgenomic RNA. Proc Natl Acad Sci USA 2004, 101(25):9429-9434. 10.1073/pnas.0400995101, 438993, 15197279.
26. Rubach JK, Wasik BR, Rupp JC, Kuhn RJ, Hardy RW, Smith JL. Characterization of purified Sindbis virus nsP4 RNA-dependent RNA polymerase activity in vitro. Virology 2009, 384(1):201-208. 10.1016/j.virol.2008.10.030, 19036396.
27. Tseng JC, Levin B, Hurtado A, Yee H, Perez de Castro I, Jimenez M, Shamamian P, Jin R, Novick RP, Pellicer A, et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 2004, 22(1):70-77. 10.1038/nbt917, 14647305.
28. Venticinque L, Meruelo D. Sindbis viral vector induced apoptosis requires translational inhibition and signaling through Mcl-1 and Bak. Mol Cancer 9:37. 10.1186/1476-4598-9-37, 2843653, 20152035.
29. Lundstrom K. Alphavirus vectors for gene therapy applications. Curr Gene Ther 2001, 1(1):19-29. 10.2174/1566523013349039, 12109136.
30. Li SD, Huang L. Non-viral is superior to viral gene delivery. J Control Release 2007, 123(3):181-183. 10.1016/j.jconrel.2007.09.004, 17935817.
31. Diebold SS, Schulz O, Alexopoulou L, Leitner WW, Flavell RA, Reis e Sousa C. Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther 2009, 16(3):359-366. 10.1038/gt.2008.164, 2655288, 19052633.
32. Tan Y, Whitmore M, Li S, Frederik P, Huang L. LPD nanoparticles--novel nonviral vector for efficient gene delivery. Methods Mol Med 2002, 69:73-81.
33. Pirollo KF, Rait A, Zhou Q, Hwang SH, Dagata JA, Zon G, Hogrefe RI, Palchik G, Chang EH. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007, 67(7):2938-2943. 10.1158/0008-5472.CAN-06-4535, 17409398.
34. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000, 18:927-974. 10.1146/annurev.immunol.18.1.927, 10837079.
35. Manders P, Thomas R. Immunology of DNA vaccines: CpG motifs and antigen presentation. Inflamm Res 2000, 49(5):199-205. 10.1007/s000110050580, 10893042.
36. Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM. Tumours can act as adjuvants for humoral immunity. Immunology 2001, 102(4):486-497. 10.1046/j.1365-2567.2001.01213.x, 1783199, 11328383.
37. Sloat BR, Shaker DS, Le UM, Cui Z. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. FEMS Immunol Med Microbiol 2008, 52(2):169-179. 10.1111/j.1574-695X.2007.00347.x, 18194342.
38. Le UM, Cui Z. Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. Int J Pharm 2006, 312(1-2):105-112. 10.1016/j.ijpharm.2006.01.002, 16457973.
39. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM, Whisnant JK. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 2004, 64(15):5074-5077. 10.1158/0008-5472.CAN-04-0926, 15289307.
40. Leitner WW, Hwang LN, Bergmann-Leitner ES, Finkelstein SE, Frank S, Restifo NP. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine 2004, 22(11-12):1537-1544. 10.1016/j.vaccine.2003.10.013, 1484509, 15063579.
41. Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 1999, 6(11):1867-1875. 10.1038/sj.gt.3301026, 10602382.
42. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M. NK cells and cancer. J Immunol 2007, 178(7):4011-4016.
43. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998, 78(1):41-45. 10.1002/(SICI)1097-0215(19980925)78:1<41::AID-IJC8>3.0.CO;2-X, 9724092.
44. McCray AN, Ugen KE, Muthumani K, Kim JJ, Weiner DB, Heller R. Complete regression of established subcutaneous B16 murine melanoma tumors after delivery of an HIV-1 Vpr-expressing plasmid by in vivo electroporation. Mol Ther 2006, 14(5):647-655. 10.1016/j.ymthe.2006.06.010, 16950655.
45. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002, 109(5):651-659. 150893, 11877473.